Featured Content

Selinexor Trials Move Nuclear Suppressor Protein-Export Inhibition Closer to the Clinic for Multiple Myeloma

XPO1 inhibition restores the ability of intranuclear tumor suppressor genes to disrupt oncoproteins; it is emerging as a promising new investigational strategy in MM.

Daratumumab Combination: New Standard of Care in Transplant-Ineligible Multiple Myeloma

The findings may support the triplet regimen as a new standard of care for these patients, according to Dr Facon.

Results From LYRA Phase 2 Study of Frontline Multiple Myeloma Therapy

Habte Yimer, MD, discusses his findings at the ASH 2018 meeting.

Phase 3 POLLUX Study: Three-Year Follow-Up

Nizar Bahlis, MD, discusses his findings at the ASH 2018 meeting.

Elotuzumab Plus Pomalidomide and Dexamethasone for R/R Multiple Myeloma

Sundar Jagannath, MD, discusses his findings at ASH 2018.

More Features>>>

Video Series

Multiple Myeloma Resources

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs